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Diagnosis of infectious diseases often requires demonstration of antibodies to the microbe (serology). A
large set of antigens, covering viruses, bacteria, fungi and parasites may be needed. Recombinant proteins
have a prime role in serological tests. Suspension arrays offer high throughput for simultaneous measure-
ment of many different antibodies. We here describe a rational process for preparation, puriﬁcation and
coupling to beads of recombinant proteins prepared in Escherichia coli derivate Origami B, to be used in a
serological Luminex suspension array. All six Gag and Env proteins (p10, p12, p15, p30, gp70 and p15E),
from the xenotropic murine leukemia virus-related virus (XMRV), were prepared, allowing the creation of
a multiepitope XMRV antibody assay. The procedure is generic and allows production of protein antigens
ready for serological testing in a few working days. Instability and aggregation problems were circum-
vented by expression of viral proteins fused to a carrier protein (thioredoxin A; TrxA), puriﬁcation via
inclusion body formation, urea solubilization, His tag afﬁnity chromatography and direct covalent cou-
pling to microspheres without removal of the elution buffer. The yield of one preparation (2–10 mg
fusion protein per 100 ml culture) was enough for 20–100 coupling reactions, sufﬁcing for tests of many
tens of thousands of sera. False serological positivity due to antibodies binding to TrxA and to traces of
E. coli proteins remaining in the preparation could be reduced by preabsorption of sera with free TrxA
and E. coli extract. The recombinant antigens were evaluated using anti-XMRV antibodies. Although
hybrid proteins expressed in E. coli in this way will not have the entire tertiary structure and posttrans-
lational modiﬁcations of the native proteins, they contain a large subset of the epitopes associated with
them. The described strategy is simple, quick, efﬁcient and cheap. It should be applicable for suspension
array serology in general.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Xenotropic murine leukemia virus-related gammaretrovirus
(XMRV) (Fig. 1) is a human gammaretrovirus of probable mouse
origin. It was detected in the year 2006 in a few percent of patients
suffering from prostate cancer [1] and subsequently, 2009, identi-
ﬁed in lymphocytes in a high percentage of patients suffering from
chronic fatigue syndrome, also called myalgic encephalomyelitis
(ME/CFS) [2]. Gammaretroviruses are well-known pathogens. They
cause leukemia, neurological disease, and immunodeﬁciency in
mice, cats and some non-human primates [3,4]. Molecular technol-
ogies such as DNA microarray, ﬂuorescence in situ hybridization
(FISH), reverse transcriptase polymerase chain reaction (RT-PCR)
and PCR have been employed for XMRV detection [5]. However,
they should be supplemented with a serological large scale XMRV
screening test. Antibodies are a good marker of past or presentlogy, Academic Hospital, 751
lomberg).
-NC-ND license.infection. XMRV virions contain the four mature core proteins: ma-
trix (MA, p15), p12, capsid (CA, p30), nucleocapsid (NC, p10), and
two envelope proteins: surface unit protein (SU, gp70) and trans-
membrane subunit envelope protein (TM, p15E) [5] (Fig. 1).
Several expression systems may be utilized to express a protein
of interest. However, regardless of approach, Escherichia coli is still
the expression host of choice due to ease of use, high growth and
production rate, cheapness, and availability. Nevertheless, the suc-
cess rate for expressing soluble eukaryotic proteins is rather low
and most post-translational modiﬁcations are absent. The product
is often in the form of a precipitate or aggregate within the bacteria
[6]. Moreover, certain amino acids at the amino terminal may
mediate rapid degradation of the recombinant protein. A com-
monly used strategy to increase solubility and stability is to fuse
the protein of interest to a protein that is known to have high sol-
ubility and stability [7–11]. Thioredoxin A (TrxA, 12 kDa) [12] has
beneﬁcial effects on solubility and expression and a small size.
A number of customized pET vectors compatible with different
E. coli derivates have been designed to improve the expression, sol-
ubility and puriﬁcation of the protein of interest. In this study, we
Fig. 1. Structure of XMRV virions and its genome. The positions of gag (group
antigen); MA (matrix), CA (capsid), NC (nucleocapsid), pol and env (envelope); SU
(surface unit) and TM (transmembrane) proteins in the virion and their coding
sequences in the integrated viral genome are shown. The location of p12 in the
virion is not accurately known. LTR: long terminal repeat.
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15] for a periplasmic and pET-32a (+) for a cytoplasmic [12,16]
expression of the target proteins.
Our main objective in this study was to express XMRV Gag and
Env recombinant proteins in E. coli, and to use these proteins as
target antigens, to detect XMRV antibodies in patients currently
or previously exposed to XMRV, using a multiple assay technology
from LuminexTM, capable of detection and quantiﬁcation of multi-
ple antibody speciﬁcities simultaneously.
In the format used by us, the system enables fast and simulta-
neous measurement of up to 100 analytes in a single microplate
well which typically contains 100 ll, using a small amount of
analyte.
The combined use of suspension arrays and our simple and
quick expression, puriﬁcation, coupling and background control-
ling system allows simultaneous measurement of antibodies to
many bacterial, fungal, protozoal or viral pathogens with high
speciﬁcity and sensitivity, ultimately resulting in a faster diagnosis.
Material and methods
Ampliﬁcation of XMRV Gag and Env target genes
Primer design
To produce recombinant proteins, we ampliﬁed the genes
encoding Gag (p30, p15, p12, P10), and Env proteins (gp70, p15E)
based on a XMRV VP62 vector (a kind gift from professor Robert
Silverman, Lerner Research Institute, Cleveland Clinic, USA) (se-
quence deposited in GenBank Accession No. EF185282). The viral
sequence was isolated from human prostatic cancer tissue.
The following primers (biomers.net GmbH) were used for
ampliﬁcation of the above fragments, Table 1. To facilitate the
cloning process of the ampliﬁed fragments into the expression vec-
tors, a suitable restriction site was incorporated in each end of each
primers. To ﬁnd out the importance of C-terminus of the Gag pro-
teins, some Gag proteins (P10 and P15) were expressed in a C-ter-
minally abridged form. In an attempt to mimick higher order
epitopes, we also expressed gp70 and P15E both together in one
protein (gp85) and as separate proteins.
PCR reaction mix
A common mixture was used for all constructs, with minor
deviations. One microliter XMRV vector (50–100 ng), 1 ll forward
primer (50 pmol/ll), 1 ll reverse primer (50 pmol/ll), 1 ll 10 mMdNTP, 10 ll phusion HF reaction buffer 5 F-518 (Finnzymes),
0.5 ll phusion DNA polymerase 2 U/ll F-530S (Finnzymes) and
36.5 ll distilled water. For gp70 and gp85, 2 ll of 10 mM dNTP
was used.
PCR ampliﬁcation program
A common program was used, with minor deviations regarding
annealing temp; for p12, both p10 constructs and long p15, 66 C.
For p30, short p15, p15E, gp70 and gp85, an annealing temperature
of 62 C was used. Furthermore, for gp70 and gp85 the fourth step
was prolonged to 2 min and step 6 to 10 min. The common PCR
program was: 98 C for 30 s; 29 cycles of 98 C for 10 s; 62 C for
30 s; 72 C for 30 s, followed by 72 C for 7 min, ending with 4 C.
Cloning and expression of XMRV recombinant proteins in bacterial
expression systems
Puriﬁcation of the ampliﬁed genes
The PCR ampliﬁed XMRV fragments were run on a 1 % agarose
gel (Seakem LE Agarose Cat No: 5000 5L, Lonza) in 0.5% TEB buffer.
The fragments were cut out from the gel and puriﬁed using a Gel
Extraction kit (Qiaquick, Cat No: 28704). The puriﬁed fragments
were cut in both ends by their suitable enzymes to remove extra
bases, and were puriﬁed on an agarose gel again for a second
round. Upon cutting, 40 ll of puriﬁed fragment was mixed with
6 ll of 10 suitable buffer, 0.6 ll of each suitable enzyme and
12.8 ll sterile water, which was incubated at 37 C for 6 h to over-
night (O/N).
Cloning of puriﬁed fragments into expression vectors
The puriﬁed fragments were ligated into three different expres-
sion vectors, pET-20b (+) ampicillin resistant equipped with a sig-
nal peptide pelB leader (Novagen), pET-39b (+) kanamycin
resistant equipped with a DsbA protein (Novagen) and pET-32a
(+) ampicillin resistant equipped with a TrxA fusion protein (Nova-
gen). The enterokinase cleavage site, situated just downstream of
TrxA, was changed to a Tobacco Etch Virus (TEV) protease cleavage
site by us (Sheikholvaezin). Most of the subsequent work was done
with pET32a. Upon ligation 2 ll cut puriﬁed vector, 7 ll fragment,
2 ll of 10 buffer for T4 DNA ligase with 10 mM ATP (#B0202S,
Biolab), 1 ll T4 DNA ligase 400000 U/ml (#M0202S, Biolab) and
8 ll of distilled water were mixed, and was incubated at room
temperature (RT) for 18 h.
Transformation and conﬁrmation of ligate
Six microliter of each ligate was added to 200 ll of competent
XL1blue cells which were incubated on ice for 30 min. This was ex-
posed to a heat shock at 42 C for 45 s, and then incubated on ice
again for 2 min. Eight-hundred microliter of LB 1 medium was
added to the transformed cells, which was shaken at 37 C for
1 h. Between 200 and 300 ll of the incubated sample was then
spread on an antibiotic containing agar plate, which was subse-
quently incubated for 16 h at 37 C.
Single colonies were picked and inoculated into 5 ml LB med-
ium with a suitable antibiotic, and were shaken O/N at 37 C. Cells
were collected and lysed, and their plasmids carrying the gene of
interest were puriﬁed using a plasmid miniprep kit (Qiaprep spin,
Cat No: 27104, Qiagen). Four microliter of each plasmid was then
cut with restriction enzymes, conﬁrmed on an agarose gel.
Sequencing of the ligate
To further conﬁrm the presence and correct sequence of the tar-
get genes, the plasmids carrying the insert were sequenced by uti-
lizing a Bigdye terminator V3.1 cycle sequencing kit (Part No:
4336917, Applied Biosystems) and an Applied Biosystems AB
3730 XL DNA sequencing machine.
Table 1
Showing the primer sequences used for ampliﬁcation of gag and env genes of XMRV. Restriction enzyme cleavage sites are bold. Amino acid sequences of the expected products
are shown within brackets.
Primer name Primer sequence
Short p10 For (58 bp)
NcoI
50 GGC GCC ATG GGA GAC CAA TGC GCC TAC TGC 30
Short p10 Rev (58 bp)
EcoRI
50 CC GAA TTC TCA GTT TGG GCA GTC CTT AGC 30 [DQCAYCKEKGHWAKDCPK]
Long p10 For (312 bp)
NcoI
50 CAT TTC GCC ATG GGA CGA GAA ACC CCG GAA GAA AG 30
Long p10 Rev (312 bp)
EcoRI
50 CC GAT GAA TTC TCA GTC ACC TAA GGT CAG GAG 30 [RETPEEREERIRREIEEKEERRRAEDEQRERERDRRRHREM
SKLLATVVIGQRQDRQGGERRRPQLDKDQCAYCKEKGHW AKDCPKKPRGPRGPRPQTSLLTLGD]
p12 For (249 bp) EcoRV 50 GGA GAT ATC CCT GCC CTT ACC CCC TC 30
p12 Rev (249 bp) SacI 50 G TCC GAG CTC TCA GAA TGC CTG GGA GGT GG 30 0 [PALTPSIKSKPPKPQVLPDSGGPLIDLLTEDPPPYGAQPS
SSARENNEEEAATTSEVSPPSPMVSRLRGRRDPPAADST TSQAF]
Short p15 For (276 bp)
NcoI
50 AG GGC GCC ATG GGA CAG ACC GTA ACT AC 30
Short p15 Rev (276 bp)
EcoRI
50 CC GAA TTC TCA GTC ATA GGC AAG TGC CTC 30 [MGQTVTTPLSLTLQHWGDVQRIASNQSVDVKKRRW
VTFCSAEWPTFNVGWPQDGTFNLGVISQVKSRVFCPG PHGHPDQVPYIVTWEALAYD]
Long p15 For (387 bp)
NcoI
50 AG GGC GCC ATG GGA CAG ACC GTA ACT AC 30
Long p15 Rev (387 bp)
EcoRI
50 CC GAT GAA TTC TCA GTA AAG GGC AGA TCG GGA C 30 [MGQTVTTPLSLTLQHWGDVQRIASNQSVDVKKRRWVTFCS
AEWPTFNVGWPQDGTFNLGVISQVKSRVFCPGPHGHPDQVP YIVTWEALAYDPPPWVKPFVSPKPPPLPTAPVLPPGPSAQPPS RSALY]
p30 For (621 bp) NcoI 50 AG GGC GCC ATG GGA TAC TGG CCG TTT TCC TCC 30
p30 Rev (621 bp) EcoRI 50 CC GAA TTC TCA CTT ATT AAA GAT CTT TTC 30 [YWPFSSSDLYNWKNNNPSFSEDPGKLTALIESVLITHQPTW
DDCQQLLGTLLTGEEKQRVLLEARKAVRGNDGRPTQLPNE VNAAFPLERPDWDYTTTEGRNHLVLYRQLLLAGLQNAGRS
PTNLAKVKGITQGPNESPSAFLERLKEAYRRYTPYDPEDPGQ ETNVSMSFIWQSAPDIGRKLERLEDLKSKTLGDLVREAEKIF NK]
p15E For
(447 bp)BamHI
50 CC GGA TCC AAA AGA GAG CCG GTG TC 30
p15E Rev (447 bp) SacI 50 GG GAG CTC TTA GCC CAT AAT GGT GGA TAT C 30 [KREPVSLTLALLLGGLTMGGIAAGVGTGTTALVATKQ
FEQLQAAIHTDLGALEKSVSALEKSLTSLSEVVLQNRR
GLDLLFLKEGGLCAALKEECCFYADHTGVVRDSMAKLRERLNQRQKLFESGQGWFEGLFNRSPWFTTLISTIMG]
gp70 For (1326 bp)
BamHI
50 CC GGA TCC ATG GAA AGT CCA GCG TTC TC 30
gp70 Rev (1326 bp) SacI 30 CTC GCC GAG CTC TCA ATA TTT AGT TTT CTT TTC 30 [MESPAFSKPLKDKINPWGPLIIMGILVRAGASVQRDSPHQ
VFNVTWKITNLMTGQTANATSLLGTMTDTFPKLYFDLCD LVGDNWDDPEPDIGDGCRSPGGRKRTRLYDFYVCPGHTV
LTGCGGPREGYCGKWGCETTGQAYWKPSSSWDLISLKRGN TPKGQGPCFDSSVGSGSIQGATPGGRCNPLVLEFTDAGKRAS
WDAPKTWGLRLYRSTGADPVTLFSLTRQVLNVGPRVPIGPN PVITEQLPPSQPVQIMLPRTPRPPPSGAASMVPGAPPPSQQPG
TGDRLLNLVEGAYLALNLTSPDKTQECWLCLVSGPPYYEGV AVLGTYSNHTSAPANCSVTSQHKLTLSEVTGQGLCIGAVPKT
HQALCNTTQKTSDGSYYLASPAGTIWACSTGLTPCLSTTVLN LTTDYCVLVELWPKVTYHSPNYVYGQFEKKTKY]
gp85 For
(1937 bp)BamHI
50 CC GGA TCC ATG GAA AGT CCA GCG TTC TC 30
gp85 Rev (1937 bp) SacI 50 CC GAG CTC TTA TTC ACG TGA TTC CAC TTC 30 [MESPAFSKPLKDKINPWGPLIIMGILVRAGASVQRDSPHQV
FNVTWKITNLMTGQTANATSLLGTMTDTFPKLYFDLCDLV GDNWDDPEPDIGDGCRSPGGRKRTRLYDFYVCPGHTVLTG
CGGPREGYCGKWGCETTGQAYWKPSSSWDLISLKRGNTPK GQGPCFDSSVGSGSIQGATPGGRCNPLVLEFTDAGKRASWD
APKTWGLRLYRSTGADPVTLFSLTRQVLNVGPRVPIGPNPV ITEQLPPSQPVQIMLPRTPRPPPSGAASMVPGAPPPSQQPGTG
DRLLNLVEGAYLALNLTSPDKTQECWLCLVSGPPYYEGVA VLGTYSNHTSAPANCSVTSQHKLTLSEVTGQGLCIGAVPKT
HQALCNTTQKTSDGSYYLASPAGTIWACSTGLTPCLSTTVL NLTTDYCVLVELWPKVTYHSPNYVYGQFEKKTKYKREPV
SLTLALLLGGLTMGGIAAGVGTGTTALVATKQFEQLQAAI HTDLGALEKSVSALEKSLTSLSEVVLQNRRGLDLLFLKEGG
LCAALKEECCFYADHTGVVRDSMAKLRERLNQRQKLFES GQGWFEGLFNRSPWFTTLISTIMGPLIVLLLILLFGPCILNR
LVQFVKDRISVVQALVLTQQYHQLKSIDPEEVESRE]
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insert, 4 ll big dye buffer 5, 1 ll of 5 pmol/ll of either For/Rev
primer, 2 ll big dye, up to 20 ll distilled water) and PCR program
(95 C for 90 s; 96 C for 10 s; 63 C for 5 s; 60 C for 90 s, 30 cycles
more) was used. After running PCR, samples were precipitated as
follows: 2 ll of (1.5 M sodium acetate, 250 mM EDTA pH 8) and
80 ll of 95% cold ethanol was added to the PCR product, which
was transferred to a 1.5 ml eppendorf tube and incubated on ice
for 20 min. Samples were centrifuged at 14000 rpm using a micro-
centrifuge (Eppendorf 5415D) for 15 min. The supernatant was re-
moved and the pellet was washed in 500 ll 70% ethanol, which
was subsequently centrifuged again. The sample pellet was air
dried in dark for 30 min, and the pellet was dissolved in 20 ll of
formamide. The suspension was then analyzed by sequencing, as
mentioned above.
Expression of XMRV target proteins
Five ll of a pET-20b (+) construct carrying the desired XMRV
genes, and 5 ll of pET-39b (+) construct carrying the desired XMRVgenes were transformed into the BL21 (DE3) E. coli expression
strain and screened on antibiotic containing agar plates. Five
microliter of pET-32a (+) construct carrying the desired genes
was also transformed into Origami B (DE3) mutated in the thiore-
doxin reductase and glutathion reductase genes. It is compatible
with pET-32a (+).Transformed bacteria were selected on the proper
antibiotic agar plates.
Colonies were picked, grown, plasmids were puriﬁed and con-
ﬁrmed on an agarose gel. One colony of each construct was inocu-
lated in 100 ml of LB 1 with the respective antibiotic (ampicillin
100 lg/ml, kanamycin 50 lg/ml). It was grown up to OD600 = 0.8,
after which 0.2 mM IPTG was added to each culture. They were
subsequently agitated gently O/N at RT.
Periplasmic expression of XMRV target proteins
To explore this avenue, induced BL21 (DE3) pET-20b (+) and
pET-39b (+) cells expressing the target proteins grown in the pres-
ence/absence of 0.4 M sucrose were collected at 10000 rpm for
10 min, using a BECKMAN J2-21M/E centrifuge. Cells were washed
Fig. 2. 10% SDS gel with recombinant XMRV proteins showing purity and molecular weight. Lane 1; Prestained standard proteins, 2; Origami B strain of E. coli, 3; TrxA-Histag
(17.6 kDa), 4; TrxA-Histag- short p10 (19.7 kDa), 5; TrxA-Histag-p12 (27 kDa), 6; TrxA-Histag-short p15 (28 kDa), 7;TrxA-Histag-p15E (34 kDa), 8; TrxA-Histag-gp85
(102.6 kDa), 9; p30 (23.6 kDa), 10; TrxA-Histag-long p10 (30.3 kDa), 11; TrxA-Histag-long p15 (32 kDa), 12; TrxA-Histag-gp70 (65 kDa), 13; Prestained standard proteins.
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pellet was dissolved in 30 mM Tris–HCl + 20% sucrose + 2 mM
EDTA, 10 less culture volume, which was agitated gently at RT
for 30 min. After centrifuging the pellet was exposed for an osmo-
tic shock by dissolving the cells in ice-cold 5 mM MgSO4, 20 less
culture volume, and agitation on ice for 20 min. Cells were centri-
fuged at 16000 rpm for 20 min. The supernatant (periplasmic frac-
tion) was saved and tested on 10% SDS PAGE [17].
Cytoplasmic expression and puriﬁcation of XMRV target proteins
under native conditions (path A of Fig. 3)
This procedure worked best for the p30 protein. Induced Ori-
gami B (DE3) pET-32a (+) cells expressing the target proteins were
collected by centrifuging at 10000 rpm for 10 min by a BECKMAN
J2-21M/E centrifuge. The cell pellet was then dissolved in 50 mM
Tris, 0.2 M NaCl, 8 mM CHAPS, 10 mM imidazole pH 8, 10 x less
compared to the culture volume, and lysed to a clear lysate by son-
ication (Sonics & materials Inc., Panbury Vibra cell, Connecticut,
USA) then centrifuged at 16000 rpm for 20 min. The supernatant
was then run on a 10 cm column packed with 1.5 ml of His tag cap-
turing ProBond Resin charged with Nickel ions (Part no: 46-0019,
Invitrogen) equilibrated by lysis buffer. The resin was washed with
lysis buffer, 10 resin volume, to remove contaminants. The target
protein was then released using lysis buffer containing 0.25 M
imidazole and with a 20 less culture volume (Fig. 3A). Fractions
(1 ml/tube) were collected and run on a 10% SDS PAGE gel [17].
After Coomassie staining and destaining the gel and visualization
of the proteins, the most pure fractions were pooled together and
were dialyzed O/N in an 800 larger sample volume in 50 mM Tris
pH 8 using a dialysis bag (Spectrapor; Spectrum) with a membrane
cut-off of 6–8 kDa to remove above all CHAPS and imidazole, but
also smaller contaminants. This resulted in about 7 mg of almost
pure fusion protein/100 ml culture (Table 2).
Removal of TrxA from fusion XMRV target proteins
Seven hundred ﬁfty lg of the dialyzed TrxA-p30 was cut by
37.5 ll TEV protease (Cat No: 10127–017, Invitrogen) for which a
cleavage site is incorporated between the TrxA and target protein
[18], in a total volume of 5.625 ml, 50 mM sodium phosphate pH
6, at 30 C O/N. The cut protein was then run on a small column
containing 0.5 ml fresh ProBond Resin (Fig. 3A). The eluate wassaved and concentrated on a stirred cell 8050 Amicon device (Mil-
lipore) using an ultraﬁltration membrane with a 10 kDa cut-off
(Millipore). This resulted in 0.1 mg, or slightly more, of pure native
p30 protein, giving a yield of 1–2 mg per 100 ml culture (Table. 2).
The presence, purity, solubility and concentration of the puri-
ﬁed p30 protein was conﬁrmed on a 10% SDS PAGE (Fig. 2), native
PAGE, and by a Nanodrop 3300 (Thermo Scientiﬁc) protein concen-
tration measurement device.
Cytoplasmic expression and puriﬁcation of XMRV target proteins from
inclusion bodies under denaturing conditions (paths B and C of Fig. 3)
Initially, attempts were done to purify the p10, p12, p15, p15E,
gp70 and gp85 proteins through a native pathway as in the case of
p30. However, this was not possible for any of the constructs. Pre-
cipitate and invisible aggregates appeared as soon as TrxA was re-
moved despite using the protein stabilizers trehalose (0.4 M),
glycerol (10%), Nv-10 (5 mg/1 mg protein), different pH, and differ-
ent salt and salt concentrations (Fig 3B). Interestingly, gp85 was
not distinguishable as a single band even in the presence of TrxA,
but just as a smear of several bands.
Consequently, due to these instability and precipitation prob-
lems associated with XMRV proteins upon removal of TrxA, with
the exception of p30, the target proteins were subsequently puri-
ﬁed under denaturing conditions in the presence of TrxA.
Origami B (DE3) with a pET-32a construct expressing the
respective target proteins after IPTG induction were collected by
centrifuging as before at 10000 rpm, whereafter the cell pellet
was dissolved in 50 mM sodium monophosphate, 0.2 M NaCl,
8 mM CHAPS, 10 mM imidazole pH 6.5 (lysis buffer), 10 less than
the culture volume. The cells were vortexed vigorously and soni-
cated to clear lysate on ice.
The cell suspension was centrifuged at 10000 rpm in a Beckman
centrifuge for 10 min to collect inclusion bodies. The supernatants
were removed and the pellet was washed once more by lysis buf-
fer. The cell pellet was then washed for a third time, this time using
a lysis buffer containing 2 M urea. The cell pellet was ultimately
dissolved in lysis buffer containing 8 M urea, 20 x less than the cul-
ture volume, by vigorous vortexing and shaking at RT for 3 h.
The denatured protein suspension was centrifuged at
16000 rpm for 20 min, whereafter the supernatant was saved and
then run on a column packed with ProBond Resin equilibrated with
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Fig. 3. Cytoplasmic expression, and puriﬁcation pathways of XMRV recombinant
proteins tested in the present work. Path A (native method), B (semi-native
method) and C (denaturing method) were evaluated. The fusion protein is shown as
thioredoxin A (TrxA), His-tag (H6), TEV (Tobacco Etch virus) protease cleavage site
(X) and XMRV protein (protein of interest, POI). Path A: (p30) involved expression in
E. coli, lysis of bacteria, removal of precipitate (black spot), puriﬁcation of
supernatant on a His-tag column, cleavage of fusion protein with TEV and removal
of the His-tagged TEV protease by a second His-tag column. Path B: illustrates the
failure to solubilize p10, p12, p15 and p15E (in long and short forms) after His-tag
puriﬁcation and TEV cleavage. Path B is identical to path A up to this step, where
these XMRV proteins were degraded or precipitated, and could not be retrieved
(symbolized by stippled lines). Solubilization and stability enhancers (⁄) were tried
to allow puriﬁcation of native XMRV protein. This did however not succeed. Path C
(p10, p12, p15, p15E, gp70, gp85, short and long forms) involved expression in
E. coli, lysis of bacteria, centrifugation and solubilization of precipitate (black spot)
using urea, and puriﬁcation in the presence of urea on a His-tag column. In this
path, puriﬁcation proceeded in two steps, ﬁrst from inclusion bodies (§), second on
a His-tag column. The proteins were puriﬁed fused together with thioredoxin A and
the His-tag, and could directly be coupled to Luminex beads.
Table 2
Showing the yield (with range of at least two experiments) of recombinant protein
constructs expressed by Origami B pET-32a.
Recombinant proteins,
from a 100 ml culture
(Recombinant)
proteins dissolved
in 8 M urea, mg
Histag puriﬁed
protein in
8 M urea, mg
Protein after
removal of
TrxA-Histag, mg
TrxA-Histag-short p10 30–34 8–10 0.0
TrxA-Histag-long p10 28–32 2–4 0.0
TrxA-Histag-p12 23–27 5–7 0.0
TrxA-Histag-short p15 28–32 9–11 0.0
TrxA-Histag-long p15 21–25 5–7 0.0
TrxA-Histag-p30 Not measured 6–8, No. urea 1–2, No. urea
TrxA-Histag-p15E 19–23 2–4 0.0
TrxA-Histag-gp70 12–16 1–3 0.0
TrxA-Histag-gp85 20–24 2–4 0.0
TrxA Not measured 5–7, No urea –
Origami B 77–83, No urea Not done –
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resin volumes of lysis buffer to remove contaminants. The target
protein was then released using lysis buffer containing 0.25 M
imidazole and 8 M urea with a volume 20 less than the culture
volume (Fig. 3C). Fractions (1 ml/tube) were collected and run on
a 10% SDS PAGE gel [17] (Fig. 2). The most pure fractions were
pooled together, and their concentration was determined using a
Nanodrop device, using elution buffer as blank.
Covalent coupling of the puriﬁed XMRV recombinant proteins to
Luminex polystyrene microspheres
Approximately 625000 carboxylated beads (Luminex xMAP
Technology Microspheres, Austin Texas 78727, USA) were washed
in 100 ll of distilled water, i.e. beads were vortexed and sonicatedin an eppendorf-tube by a small ultrasonic cleaner CD-2800 (Kjell
& Co, made in China) for 20 s, and centrifuged at 14000 rpm, using
an eppendorf centrifuge 5415D, for 3 min. The supernatant was re-
moved and 80 ll of 100 mM monobasic sodium phosphate (NaH2-
PO4) pH 6.2 were added to the bead pellet, whereafter the
suspension was vortexed and sonicated. Ten microliter of 25 mg/
ml sulfo-NHS (Cat No: 24510, Thermo science) diluted in sterile
water, and 10 ll of 25 mg/ml EDC (1-ethyl-3-dimethyl aminopro-
pylcarbodiimide hydrochloride (CAS# 25952–53-8, PIERCE) diluted
in sterile water were added to the sonicated bead suspension,
which was vortexed gently and incubated with gentle shaking at
RT for 20 min. Beads were then centrifuged, supernatant was re-
moved and the pellet was washed in 250 ll of 50 mM MES (2-
[N-morpholino] ethanesulfonic acid sodium salt, CAS#: 71119-
23-8, Sigma) pH5. This washing step was repeated once.
Hundred microliters MES buffer was added to the bead pellet,
which was vortexed and sonicated. To this suspension, 50–
100 lg of the protein of interest was added, and the total volume
of the protein-bead suspension was brought up to 500 ll by MES
buffer. This was incubated at RT for 2 h, on gentle shake. After cen-
trifuging and removal of supernatant, the coupled beads were
washed with 500 ll of StabilGuard (Cat No: SG01-1000, SurModics,
USA) buffer. This washing step was repeated twice but in 1 ml Sta-
bilGuard buffer each time. The coupled beads were resuspended in
100 ll StabilGuard and were then ready for suspension array
serology.
Testing of different coupling conditions
During the course of the development of a uniﬁed protocol, dif-
ferent puriﬁcation pathways of the expressed recombinant XMRV
proteins were chosen. Because of this, proteins were coupled to
the Luminex microsphere beads under different conditions.
p30 Was coupled in 50 mM sodium phosphate buffer pH 6,
while other protein constructs were coupled in the mentioned buf-
fer containing different concentrations of urea (1, 3, 6 and 8 M),
imidazole and CHAPS with a ﬁnal pH of 6.5.
Sera used to detect XMRV proteins
Different sera were used to detect different recombinant XMRV
proteins: one mouse post XMRV immunization serum and one nor-
mal (a kind gift from Dr. Yasuhiro Ikeda, Department of Molecular
Medicine, Rochester, Minnesota, USA) were used for p10 and p15E
(1:25), hyperimmune goat sera against p30, p12 and p15 as well as
normal goat control serum were kindly provided by Dr. Sandra
Ruscetti, Laboratory of cancer prevention, NCL, USA. They were
tested in a dilution of 1:100. Goat hyperimmune serum against
gp70, and gp85, and normal goat serum was kindly provided by
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Fig. 4. Showing the interaction between recombinant XMRV proteins and bead
controls ononehand, andanti-XMRVseraandcontrol seraon theother.MFI = Median
Fluorescence Intensity. (A) Mouse anti XMRV serum, (B) Goat anti-p12 antibody, C.
Goat anti-p15 antibody, (C) Goat anti-p30 antibody, (D) Goat anti-p30 antibody, (E)
Mouse anti-XMRV serum, (F) Goat anti-gp70 serum. Negative control sera were from
a not immunized goat, and an uninfected mouse, respectively. Control beads were
Origami E. coli lysate, TrxA and naked (uncoupled carboxylated) bead. The antigen
usedwithnegative control sera ismarkedwith ‘‘§’’.Mouse anti-XMRV serawere used
in (A) to study the antigenicity of p10, and in (E) to study the antigenicity of p15E.
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Atlanta, USA. It was also tested at a dilution of 1:100. To avoid pos-
sible cross reactivity with the TrxA fusion tag and with remnants of
E. coli proteins on the beads, all sera and antibodies were preincu-
bated with free TrxA (2 lg) and E. coli lysate (100 lg) per 50 ll di-
luted antiserum, respectively, for 30 min on shake.Suspension array serology
Approximately 5000 of each of the 6 XMRV protein coupled
beads were mixed with an equal amount of TrxA-bead, Origami-
bead and naked-bead as negative controls in a ﬁnal volume of
50 ll StabilGuard applied to a Millipore 96 well ﬁlter plate (MX-
plate) already soaked with 100 ll PBS. Fifty microliters of speciﬁc
antibodies for each protein diluted in StabilGuard buffer were
added to separate wells and, incubated for 30 min on gentle shake
at RT, washed with PBS three times. Thereafter 100 ll StabilGuard
buffer containing a ﬁnal concentration of 2 lg/ml biotinylated pro-
tein-G (Cat No: 29988, Thermo Science) was added to each well.
The samples were incubated for another 30 min. Wells were
washed as before, and 100 ll of StabilGuard diluent containing a
ﬁnal concentration of 2 lg/ml Streptavidin R-PE conjugate (Cat
No: SA1004-4, Invitrogen) was added to each well. The samples
were incubated for 15 min on shake in the dark at RT. Conjugated
samples were washed 3 times as before by PBS. Finally, 100 ll
PBS were added to each well, and samples were analyzed by the
Luminex multianalyzer (Luminex 200, Luminexcorp, Austin, Tx).Results
All Gag (p30, p15, p12, p10) and Env (p15E, gp70, gp85) XMRV
fusion proteins were successfully expressed in the cytoplasmic
mode (Fig. 2), when using Origami B (DE3) with a pET-32a (+) con-
struct in high amount (Table. 2). However, these proteins were
puriﬁed under two different conditions, native and denatured.
Their ﬁnal amount, instability and tendency to precipitate and
aggregate after removal of the TrxA fusion partner varied.
On the contrary, neither Gag nor Env XMRV proteins were sol-
uble and detectable when puriﬁed from any construct through a
periplasmic expression pathway, using BL21 (DE3) pET-20b (+)/
pET-39b (+) constructs as an expression system.
The cytoplasmically expressed p30 protein, was puriﬁed in a
native form i.e. soluble, stable and antigenically active, and was
coupled to beads easily. This was not possible for any of the other
cytoplasmically created XMRV recombinant proteins. They formed
either a visible precipitate or invisible aggregates immediately
after removal of TrxA. We therefore decided to solubilize them
from inclusion bodies with urea and couple them to the Luminex
beads as fusion proteins in the presence of 0.25 M imidazole,
8 mM CHAPS and 8 M urea, obtained directly after elution from a
His-tag capturing Probond resin column without any dialysis
(Fig. 2). Coupling in the presence of 3 M urea worked best, but
we tested dilutions ranging from 1.5 to 8 M. Judging from the
MFI of antibodies speciﬁc for the respective protein, covalent cou-
pling was as efﬁcient under these conditions as under the other
conditions (data not shown).
The tested paths for expression and puriﬁcation of XMRV pro-
teins are depicted in Fig. 3A (native method), Fig. 3B (semi-native
method), and Fig. 3C (denaturing method). Path C is the most gen-
eral. It is used when facing insolubility, and path B when facing
instability problems after removal of the fusion partner. These re-
combinant proteins diverged slightly in terms of reactivity with
XMRV antibodies, possibly due to different antibody speciﬁcity,
concentration, protein conformation, or source of animal used for
immunization and antibody production (Fig. 4A–F).
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TrxA-gp85 fusion-proteins and p30 native protein reacted strongly
with their XMRV speciﬁc antisera (Fig. 4A–F), although long TrxA-
p10 showed some small cross reactivity with the goat anti-p15
antibody, and TrxA-gp85 with goat anti-p30 antibody (Fig. 4C,
D). We did not have a speciﬁc anti-p10 antiserum, but the serum
from an XMRV infected Mus pahari proved to react strongly with
it, providing evidence for relevant antigenicity of the TrxA-p10
protein (Fig. 4A, E). Serum from the same mouse before infection,
as well as sera from other uninfectedMus pahari, did not react with
the short p10 fusion protein.
Surprisingly, a longer variant of the p10 protein lost antigenicity
with sera from XMRV-infected Mus pahari. A short version of p10
reacted strongly with the same sera (Fig. 4A). On the contrary, a
long p15 protein increased its antigenicity almost to the double
compared to the C-terminally short variant (Fig. 4C).
Furthermore, the precursor gp85 which was most probably de-
graded to smaller fragments during puriﬁcation, showed almost as
high antigenicity as compared to the gp70 alone (Fig. 4F).
Preincubation of sera with free TrxA was able to reduce the
background. The effect was optimal after 30 min of preincubation
with 2 lg thioredoxin per 50 ll serum preincubation mixture
(Fig. 5A). Likewise, the E. coli extract containing bead signaled a
high content of E. coli antibodies in some human sera (data not
shown). This unspeciﬁc reaction was also seen with several of
the recombinant proteins. It could be reduced to almost nil for
most such sera after a preincubation with 100 lg E. coli extract
for 30 min (Fig. 5B).A
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Fig. 5. Absorption of antibodies binding to TrxA and E. coli antigens. A. Blocking of TrxA
human (blood donor) sera.Discussion
Recombinant proteins are often optimal as antigens in sero-
logical assays. They mimic many of the linear and conforma-
tional epitopes of the original native protein. However,
properties of proteins which are normally produced in vertebrate
cells may only be imperfectly mimicked by recombinant proteins
produced in bacteria. Moreover, production of such recombinant
proteins is ‘‘out of cellular context’’ and faces a number of prob-
lems including degradation, aggregation, codon usage differences
and toxicity to the bacterial host. These may be hard to predict
and to avoid. The preferred expression and puriﬁcation of fusion
proteins described here, Fig. 3 path ‘‘C’’, sacriﬁces some of the
posttranslational modiﬁcations and tertiary structure which
might have given optimal native antigenicity. A similar trade-
off between the full antigenicity of a native protein and the
more restricted antigenicity of a partially denatured protein is
made in Western blot serology, which is widely used. In the pre-
sented technique, the risk of false serological reactions due to
the fusion partner and E. coli origin is diminished by preincuba-
tion of sera with fusion partner protein and E. coli extract. The
simplicity and rapidity of the technique will probably outweigh
most of these disadvantages. Although the production of recom-
binant proteins is becoming more rational [19–21] we are not
aware of a previous similar simple and rapid expression, puriﬁ-
cation and coupling process for use in a high throughput Lumin-
ex suspension array serology system.4 µg 10 µg
rent amounts of free TrxA
BD
61
ith Origami E. coli proteins
0 µg
10 µg
50 µg
100 µg
binding antibodies in goat serum. B. Blocking of E. coli protein binding antibodies in
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immune responses to retroviral infections. This is also the case in
experimental XMRV infection [22].
Antibodies to XMRV virus were reported to occur in 19 of 30 CFS
blood samples from ME/CFS patients, but not in 16 healthy control
specimens (4). It is of great importance to clarify the frequency of
XMRV infection in humans.
To reach this goal, we evaluated several E. coli expression sys-
tems with a range of strains, expression vectors and expression
pathways. Cytoplasmic or periplasmic expression, induction with
different amounts of IPTG, temperatures and times were com-
pared. The periplasm of E. coli is an oxidative environment contain-
ing several chaperones necessary for refolding of nascent proteins
arriving from the cytoplasm [23–25]. However, precipitate and
aggregates can form even in the periplasm. We tested refolding
enhancers and periplasmic space expanders such as sucrose [26–
29] without great success. Another problem is that certain amino
acids such as Phe, Leu, Trp, Tyr, Arg, and Lys at the N-terminus of
a protein can lead the protein to degradation according to the
‘‘N-end rule’’ [30]. Replacing these amino acids with others, or
using a suitable fusion partner at the N-terminus of such proteins
may increase protein half-life. It has also been shown that the sol-
ubility of constructs with a fusion partner joined to the protein of
interest is inﬂuenced by whether the protein domains emerging
ﬁrst from the ribosome normally fold into a soluble or an insoluble
state [31]. We therefore expressed the desired XMRV proteins to-
gether with a fusion protein localized at the N-terminus.
Among expression vectors equipped with different fusion pro-
teins, we choose pET-32a (+) which carriesTrxA. TrxA has been
shown to be one of the best fusion proteins because of its tendency
to increase expression and its small size [12]. pET-32a (+) is com-
patible with the E. coli derivate Origami B (DE3), which is mutated
in both thioredoxin reductase and glutathione reductase, two en-
zymes that prevent disulphide bond formation in the cytoplasm
of E. coli, whereby they facilitate the disulﬁde bond formation
and refolding of target proteins under gentle condition in the cyto-
plasm of E. coli.
Success was obtained when this cytoplasmic expression path-
way (Fig. 3A, B, and C) was chosen. However, in most cases, this
method was not devoid of problems either, when removing TrxA.
Despite several attempts under different conditions, large precipi-
tates or invisible aggregates were formed immediately after re-
moval of TrxA, although protein solubilizers and stabilizers were
tried (Fig. 3B). These observations were conﬁrmed by centrifuging
the sample, measuring concentration and running the protein sam-
ple on native gel. However, p30 (Fig. 3A) and TrxA alone were
exceptions.
A very convenient aspect of path C was that the proteins could
be coupled directly to color coded Luminex beads after puriﬁcation
on a His-Tag column, in the presence of high concentrations of
urea, imidazole and CHAPS. These molecules lack primary amino
groups, which are are necessary for carbodiimide and sulfo-NHS
catalysed coupling to carboxyl residues on the bead. Thus, the dif-
ferent forms of nitrogen in the three eluants were proven to not
interfere with the coupling. We are not aware of previous publica-
tions which took advantage of this simpliﬁcation.
Thus, the preferred conditions (path C in Fig. 3) gave several
advantages: (1) A volume of 100 ml culture sufﬁced to produce
up to 10 mg of protein. (2) The use of 0.2 mM IPTG gave a more
moderate expression than the more customary 0.5–2 mM concen-
trations. This reduces the negative effects on bacterial growth and
protein folding [32–34]. (3) The puriﬁcation from inclusion bodies
enabled higher protein yield. The protein was easily solubilized
and separated from contaminants by sodium chloride, CHAPS
and urea. (4) The dual puriﬁcation from inclusion bodies and via
His-tag, is simple and avoids further lengthy and protein-damagingand consuming steps. (5) Coupling to Luminex beads is done di-
rectly after His-tag puriﬁcation, without further manipulations.
The coupling yield was not adversely affected by the presence of
the eluants urea, imidazole and CHAPS detergent. (6) The whole
process, with protein puriﬁcation, coupling to Luminex beads and
quality control via a Luminex antibody detection assay did not take
more than three working days.
Because of the instability and aggregation problem associated
with the XMRV proteins (except for p30), they were ultimately ex-
pressed and puriﬁed with retained TrxA under denaturing condi-
tions using 8 M urea. This procedure gave a higher yield of the
protein of interest (200–300 mg/l culture before and 20–100 mg/l
after puriﬁcation using a His-tag capturing resin) and higher purity
(up to 95%) with the exception of gp85, which appeared to be de-
graded during the puriﬁcation (Fig. 2).
All the fusion proteins yielded a high antigenicity with appropri-
ate antiserawhen coupled in the presence of urea, 8 mMCHAPS and
0.25 M imidazole. Free TrxA was used in the serum dilution ﬂuid to
blockanynon-speciﬁcantibodieswhichmightbind toTrxA (Fig. 5A).
A bead coupled with TrxA alone was used to monitor the presence
and degree of remaining TrxA antibodies. Likewise, antibodies reac-
tivewith E. coli could be blockedby including E. coli lysate during the
preincubation (Fig. 5B). Any remaining not blocked E. coli antibodies
were monitored using a bead coupled with E. coli lysate.
XMRV serology has its special problems. The primary one is that
there are no unambiguously positive human sera which can be
used as positive controls. A convincing Western blot from a human
serum has not yet been published. However, there are experimen-
tally infected animals (macaques and Mus pahari mice) which de-
velop a range of XMRV antibodies, with positive Western blots
[5]. We were fortunate to obtain Mus pahari antisera [35]. The sev-
eral XMRV antigens on beads in a suspension array is in effect an
‘‘instant Western blot’’, which is faster, more quantitative and
more cost-effective than traditional Western Blot or line immuno-
blot assays. The system uses smaller sample volumes than these
blot techniques. It is internally controlled by several control beads,
and therefore safe.
The more or less dramatic inﬂuence of the length of the ex-
pressed protein is not unexpected, but illustrates the need to eval-
uate, both bioinformatically and experimentally, optimal forms of
the protein. Previous publications on XMRV proteins [19] stressed
the need to test several expression and puriﬁcation pathways in
parallel to reach an optimal path with little time delay. Although
our system must be tested in a larger context, the experience re-
ported here indicates that a more unitary approach is possible.
Taken together, based on our results, we consider our method of
recombinant protein preparation in combination with Luminex
technology to provide reliable, relatively cheap, simple and quick
detection of antibodies in animal and human sera. The ease of anti-
gen preparation and antibody detection facilitate multiplex appli-
cations for a variety of infections.Conclusion
All major XMRV proteins, from Gag (p30, p15, p12, p10) and Env
(gp70, p15E, gp85) were easily and quickly produced in large
amounts using an E. coli expression system via a cytoplasmic path-
way. However, these new recombinant proteins behaved differ-
ently from each other in terms of solubility, stability, coupling
ability and thereby antigenicity.
Moreover, a long variant of the p10 protein lost antigenicity
with sera from XMRV-infected mice. The shorter counterpart re-
acted strongly. The long form of p15 protein increased its antige-
nicity almost to the double compared to the C-terminally short
184 A. Sheikholvaezin et al. / Protein Expression and Puriﬁcation 80 (2011) 176–184variant. The precursor gp85, although degraded, showed almost as
high antigenicity as compared to the gp70 alone.
One Gag protein (p30) could be puriﬁed in a native, pure and
antigenically active form, while four others (p15, p12, p10 and
p15E) had to remain connected to TrxA to retain their stability.
The Env proteins gp70 and gp85 also had to be puriﬁed as TrxA fu-
sion proteins in the presence of urea. All urea denatured (except
p30) proteins were puriﬁed on a His trap column and covalently
coupled to suspension array beads in the presence of the eluants
without any further treatment, and had a high reactivity with
appropriate antisera.
The chosen expression, puriﬁcation and coupling path sacriﬁces
some of the posttranslational modiﬁcations and tertiary structure
which may have given optimal antigenicity. However, the simplic-
ity and rapidity of the technique will probably outweigh these dis-
advantages in many serological applications.
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